论文部分内容阅读
目的：观察重组人血管抑素（ recombinant human angiostatin,rhAGN）对鼻咽癌皮下移植瘤生长的抑制作用，探讨其应用价值。方法：应用 MTT法观察 rhAGN对 CNE 1鼻咽癌细胞和 HDMEC血管内皮细胞增殖的影响；建立 CNE 1鼻咽癌裸鼠皮下移植瘤模型，皮下注射不同剂量 rhAGN，治疗期为 30天，观察肿瘤体积和重量变化。 结果： (1)在 0.5μ g/ml、 1.0μ g/ml和 2.0μ g/ml测试浓度下，培养 72 h， rhAGN对 CNE 1细胞生长抑制率为 3.4％、 5.2％和 5.9％，对 HDMEC细胞生长抑制率为 39.4％、 65.3％和 89.7％； (2)rhAGN剂量为 50 mg· (kg· d)－ 1、 100mg· (kg· d)－ 1和 200mg· (kg· d)－ 1时的抑瘤率分别为 32.3％、 64.0％和 83.2％。 结论： rhAGN在体外对 CNE 1细胞增殖无明显抑制作用，在体内能显著抑制 CNE 1鼻咽癌移植瘤的生长，具有潜在的应用前景。
OBJECTIVE: To observe the inhibitory effect of recombinant human angiostatin (rhAGN) on the growth of nasopharyngeal carcinoma xenografted tumor and to explore its value. Methods: The effect of rhAGN on the proliferation of CNE 1 nasopharyngeal carcinoma cells and HDMEC vascular endothelial cells was observed by MTT method. The CNE 1 nasopharyngeal carcinoma xenografts model was established by subcutaneous injection of different doses of rhAGN. The treatment period was 30 days. Volume and weight change. Results: (1) The growth inhibitory rates of rhAGN on CNE 1 cells were 3.4%, 5.2% and 5.9% at 72 h after incubation at the concentrations of 0.5 μg / ml, 1.0 μg / ml and 2.0 μg / ml, The growth inhibition rates of HDMEC were 39.4%, 65.3% and 89.7% respectively. (2) The dose of rhAGN was 50 mg · kg -1 d -1 and 100 mg · kg -1 d and 200 mg · kg -1 d The tumor inhibition rates at 1 were 32.3%, 64.0% and 83.2%, respectively. CONCLUSION: rhAGN has no significant inhibitory effect on the proliferation of CNE 1 cells in vitro, and can significantly inhibit the growth of CNE-1 nasopharyngeal carcinoma in vivo and has potential application.